Cinolazepam

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Cinolazepam
Cinolazepam.svg
Cinolazepam3d.png
Clinical data
Trade namesGerodorm
AHFS/Drugs.comcinolazepam
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability90–100%
MetabolismHepatic
Elimination half-life3.8 hours[1]
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC18H13ClFN3O2
Molar mass357.8 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
 ☒N☑Y (what is this?)  (verify)

Cinolazepam[2] (marketed under the brand name Gerodorm)[3] is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Due to its strong sedative properties, it is primarily used as a hypnotic.

It was patented in 1978 and came into medical use in 1992.[4] Cinolazepam is not approved for sale in the United States or Canada.

References[edit]

  1. ^ "ZUSAMMENFASSUNG DER MERKMALE DES ARZNEIMITTELS" (Press release) (in Austrian). Austria: G.L. Pharma GmbH. Bundesamt für Sicherheit im Gesundheitswesen. October 2018. Archived from the original on 2019-01-02. Retrieved 2019-01-02.CS1 maint: Unrecognized language (link)
  2. ^ US Patent 4388313 Novel 3-hydroxy-1,4-benzodiazepine-2-ones and process for the preparation thereof
  3. ^ Lannacher Romania (1999). "Gerodorm". Produse Gerot inregistrate in Romania (in Romanian). Archived from the original on 11 October 2006. Retrieved 17 August 2006.
  4. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 530. ISBN 9783527607495.

External links[edit]